Employing the drug decitabine or 5’-aza-2-deoxy-cytodine they demonstrated that 21/21 patients with AML and p53 mutations responded to this drug treatment with tumor reductions, while 78 patients with a wild type p53 gene did not respond. This evidence concerns the gene TP53 and acute myeloid leukemia.